Search

Author/Creator Meergans, Matthias

1. 069 Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who are newly diagnosed with relapsing-remitting multiple sclerosis (RRMS): subgroup analysis of advance. Issue 6 (24th May 2018)

Authors:
Newsome, Scott D; Arnold, Douglas L; Yun, Jang; Meergans, Matthias; Naylor, Maria L
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 89:Issue 6(2018)
Page Start:
A28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. Issue 1 (December 2016)

Authors:
Ziemssen, Tjalf; Gass, Achim; Wuerfel, Jens; Bayas, Antonios; Tackenberg, Björn; Limmroth, Volker; Linker, Ralf; Mäurer, Mathias; Haas, Judith; Stangel, Martin; Meergans, Matthias; Harlin, Olof; Hartung, Hans-Peter
Journal:
BMC neurology
Issue:
Volume 16:Issue 1(2016)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis. (August 2018)

Authors:
Arnold, Douglas L.; Shang, Shulian; Dong, Qunming; Meergans, Matthias; Naylor, Maria L.
Journal:
Therapeutic advances in neurological disorders
Issue:
Volume 11(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗